The Q1 2026 MSO earnings: who's surviving compression, who isn't

The Q1 2026 earnings cycle is mostly behind us, and the headline read is unchanged: wholesale price compression is doing what it has been doing for three years, limited-license east-coast markets are saving the multi-state operators, and the operators without east-coast exposure are running out of runway.

The wholesale picture

Aggregating disclosures and weighted price-per-pound data from Cannabis Benchmarks and LeafLink, wholesale flower across the mature legal markets is down roughly 9 percent year over year. California and Michigan continue to be the most punitive, with average wholesale pounds trading at levels that no traditional cultivator with conventional debt service can sustain. Massachusetts and Maryland — markets that were richly priced two years ago — are now compressing toward those western benchmarks.

Who outperformed

The pattern was consistent: operators with meaningful Ohio, Pennsylvania, New York, or Maryland exposure delivered EBITDA margins 8 to 14 points above operators concentrated in legacy western markets. The mechanism is straightforward — limited-license markets price retail closer to medical-program benchmarks, and competition is constrained by licensing caps.

Cash flow remains the gating problem

EBITDA is not cash. Three of the top ten MSOs by revenue reported negative operating cash flow this quarter, and excise tax arrears continue to be the dominant working capital story. The IRS settled one large MSO 280E obligation during the quarter, and that company's stock rallied on the news — a clean indicator of how much the rescheduling overhang is mispricing equity.

M&A: retail is consolidating, wholesale isn't yet

The deals that closed this quarter were almost entirely retail consolidation — strong operators picking up underperforming stores in distressed markets at single-digit revenue multiples. The wholesale brand consolidation thesis — the idea that flower brands will eventually consolidate the way alcohol brands did — is still a 2027-or-later story. Brand equity in cannabis remains thin enough that acquired brands routinely fail to retain shelf presence after deal close.

What we'll be watching next quarter

Three reads to take into Q2:

1. Whether the operators with negative operating cash flow disclose covenant amendments or further capital raises.
2. The pace of New York retail openings, which has been slower than the company forecasts assumed.
3. Any pricing inflection in the western markets — even a flattening of the decline curve would meaningfully change EBITDA trajectories.